Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
0.00% $0.534
America/New_York / 18 jan 2023 @ 15:56
RATING 2023-02-03 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Buy | |
P/E: | Neutral | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
Revenue | ||||||
Gr.Profit | n/a | n/a | n/a | |||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
N/A |
Company: PE 0 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.428 - 0.580 ( +/- 15.09%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-18 | Martell Bridget A | Buy | 0 | |
2023-10-18 | Orbach Pini | Buy | 0 | |
2023-10-18 | Golan Roy | Buy | 0 | |
2023-01-19 | Amoon Growth Fund Limited Partnership | Sell | 2 991 473 | Common Stock |
2023-01-19 | Sidransky David | Sell | 12 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
-97.53 |
Last 84 transactions |
Buy: 4 327 382 | Sell: 8 482 924 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.534 (0.00% ) |
Volume | 0.138 mill |
Avg. Vol. | 0.0505 mill |
% of Avg. Vol | 272.62 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.